Research programme: CC-chemokine receptor 3 antagonists - Millennium/Roche BioscienceAlternative Names: CCR3 antagonists research programme - Millennium/Roche Bioscience
Latest Information Update: 23 Aug 2002
At a glance
- Originator Millennium Pharmaceuticals
- Developer Millennium Pharmaceuticals; Roche Palo Alto LLC
- Mechanism of Action CCR3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma; Hypersensitivity
Most Recent Events
- 26 Jan 2000 LeukoSite has been merged into Millennium Pharmaceuticals
- 05 Jun 1998 New profile
- 05 Jun 1998 Preclinical development for Allergy in USA (PO)